Maximal antagonist effect in saline-treated rats
| Antagonist | Elevations in Reward Thresholds (% of baseline) | Dose | Somatic Signs (overall number) | Dose | Place Aversion (change in time—s) | Dose |
|---|---|---|---|---|---|---|
| Mecamylamine (s.c.) | 107 | 1.14 mg/kg | 6 | 0.29 mg/kg | −100 | 4.0 mg/kg |
| DHβE (s.c.) | 99 | 1.0 mg/kg | 9 | 6.0 mg/kg | n/a | n/a |
| Chlorisondamine (s.c.) | 107 | saline | 37 | 1.0 mg/kg | n/a | n/a |
| Chlorisondamine (i.c.v.) | 129 | 10 μg | 21 | 10 μg | n/a | n/a |
| Naloxone (s.c.) | 109 | 4.0 mg/kg | 23 | 8.0 mg/kg | −93 | 0.24 mg/kg |
Maximal effects of nicotinic antagonists and an opioid antagonist on reward thresholds, somatic signs, and place aversions in saline-treated rats expressed as a percentage of the mean 5-day baseline threshold, mean overall number of signs observed during a 10-minute observation, and the mean difference in time (seconds) spent in the antagonist-paired compartment before conditioning compared to after conditioning, respectively.
n/a, not applicable.
Data for DHβE were taken from Epping-Jordan et al. (1998).